JP2021528367A5 - - Google Patents
Info
- Publication number
- JP2021528367A5 JP2021528367A5 JP2020561892A JP2020561892A JP2021528367A5 JP 2021528367 A5 JP2021528367 A5 JP 2021528367A5 JP 2020561892 A JP2020561892 A JP 2020561892A JP 2020561892 A JP2020561892 A JP 2020561892A JP 2021528367 A5 JP2021528367 A5 JP 2021528367A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- administered
- dose
- adenovirus
- cell
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024078396A JP2024105526A (ja) | 2018-05-16 | 2024-05-14 | 免疫応答を誘導するための組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1807932.7 | 2018-05-16 | ||
| GBGB1807932.7A GB201807932D0 (en) | 2018-05-16 | 2018-05-16 | Compositions and methods for inducing an immune response |
| PCT/EP2019/062694 WO2019219851A1 (en) | 2018-05-16 | 2019-05-16 | Compositions for inducing an immune response |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024078396A Division JP2024105526A (ja) | 2018-05-16 | 2024-05-14 | 免疫応答を誘導するための組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021528367A JP2021528367A (ja) | 2021-10-21 |
| JP2021528367A5 true JP2021528367A5 (https=) | 2022-05-18 |
| JPWO2019219851A5 JPWO2019219851A5 (https=) | 2022-05-18 |
Family
ID=62623405
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561892A Withdrawn JP2021528367A (ja) | 2018-05-16 | 2019-05-16 | 免疫応答を誘導するための組成物 |
| JP2024078396A Pending JP2024105526A (ja) | 2018-05-16 | 2024-05-14 | 免疫応答を誘導するための組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024078396A Pending JP2024105526A (ja) | 2018-05-16 | 2024-05-14 | 免疫応答を誘導するための組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12246038B2 (https=) |
| EP (1) | EP3793581A1 (https=) |
| JP (2) | JP2021528367A (https=) |
| KR (1) | KR102810080B1 (https=) |
| CN (2) | CN112088012A (https=) |
| AU (1) | AU2019270424A1 (https=) |
| CA (1) | CA3097951A1 (https=) |
| GB (1) | GB201807932D0 (https=) |
| MX (1) | MX2020012150A (https=) |
| SG (1) | SG11202010862VA (https=) |
| WO (1) | WO2019219851A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| KR20220115569A (ko) | 2019-11-18 | 2022-08-17 | 얀센 바이오테크 인코포레이티드 | 돌연변이 calr 및 jak2에 기반한 백신 및 이의 용도 |
| US12295997B2 (en) | 2020-07-06 | 2025-05-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| EP4444347A1 (en) * | 2021-12-07 | 2024-10-16 | Barinthus Biotherapeutics (UK) Limited | Vaccine boost methods and compositions |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0203419D0 (en) * | 2002-02-13 | 2002-04-03 | Oxford Biomedica Ltd | Peptide |
| GB201006405D0 (en) | 2010-04-16 | 2010-06-02 | Isis Innovation | Poxvirus expression system |
| US9828414B2 (en) | 2012-10-28 | 2017-11-28 | Bavarian Nordic A/S | Pr13.5 promoter for robust T-cell and antibody responses |
-
2018
- 2018-05-16 GB GBGB1807932.7A patent/GB201807932D0/en not_active Ceased
-
2019
- 2019-05-16 CA CA3097951A patent/CA3097951A1/en active Pending
- 2019-05-16 US US17/055,056 patent/US12246038B2/en active Active
- 2019-05-16 CN CN201980030633.8A patent/CN112088012A/zh active Pending
- 2019-05-16 MX MX2020012150A patent/MX2020012150A/es unknown
- 2019-05-16 SG SG11202010862VA patent/SG11202010862VA/en unknown
- 2019-05-16 KR KR1020207036057A patent/KR102810080B1/ko active Active
- 2019-05-16 EP EP19734251.2A patent/EP3793581A1/en active Pending
- 2019-05-16 AU AU2019270424A patent/AU2019270424A1/en not_active Abandoned
- 2019-05-16 CN CN202411963750.9A patent/CN119770632A/zh active Pending
- 2019-05-16 WO PCT/EP2019/062694 patent/WO2019219851A1/en not_active Ceased
- 2019-05-16 JP JP2020561892A patent/JP2021528367A/ja not_active Withdrawn
-
2024
- 2024-05-14 JP JP2024078396A patent/JP2024105526A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024105526A5 (https=) | ||
| JP2021528367A5 (https=) | ||
| CN100379865C (zh) | 用于产生cd8t细胞免疫应答的试剂盒及其用途 | |
| CN116732101A (zh) | 用于治疗hbv的手段和方法 | |
| Baur et al. | Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses | |
| JP2011500718A5 (https=) | ||
| JP2020528911A5 (https=) | ||
| JP2024105526A (ja) | 免疫応答を誘導するための組成物 | |
| CN105658790A (zh) | 疫苗组合物 | |
| JP2023503858A (ja) | ４－１ｂｂｌアジュバント添加した組み換え改変ワクシニアウイルスアンカラ（ｍｖａ）の医学的使用 | |
| JP2010523138A5 (https=) | ||
| Haq et al. | Evaluation of recombinant adenovirus vectors and adjuvanted protein as a heterologous prime-boost strategy using HER2 as a model antigen | |
| JP2025084850A5 (https=) | ||
| JPWO2019219851A5 (https=) | ||
| CN116322740A (zh) | 免疫抑制的治疗 | |
| JPWO2021019235A5 (https=) | ||
| CN102159241A (zh) | 用于增强免疫应答的泰帕森(Tapasin)增加 | |
| HK40099982A (zh) | 用於治疗hbv的手段和方法 | |
| HK40096275A (zh) | 免疫抑制的治疗 | |
| CN112399855A (zh) | 作为佐剂的溶瘤病毒 | |
| NZ783284A (en) | Modified adenoviruses | |
| JPWO2021209897A5 (https=) | ||
| AU2010226945A1 (en) | Vaccination regimen |